When should a nurse hold metformin?

Hold metformin when eGFR is below 30 mL/min/1.73 m2, during acute or chronic metabolic acidosis including DKA, for iodinated contrast in at-risk patients per labeling, during acute illness with dehydration or hypoperfusion, before major surgery per protocol, and when lactic acidosis is suspected. Reassess eGFR after contrast and restart only if renal function is stable.

What eGFR is required to start or continue metformin?

Metformin is contraindicated when eGFR is below 30. Initiation is not recommended when eGFR is 30 to 45. If eGFR falls below 45 while on therapy, assess benefit versus risk of continuing. Discontinue if eGFR falls below 30. Obtain eGFR before initiation and at least annually, or more often in older adults and patients at risk for renal decline.

Does metformin cause hypoglycemia by itself?

Metformin alone rarely causes hypoglycemia, but hypoglycemia risk increases when combined with insulin or insulin secretagogues. Lower doses of the insulin or secretagogue may be required. Monitor blood glucose more frequently when combination therapy starts or doses change.

What are warning signs of metformin-associated lactic acidosis?

Symptoms may be subtle: malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Severe cases may include hypotension and resistant bradyarrhythmias. Laboratory findings can include elevated lactate, anion gap acidosis without ketonuria, and metformin levels generally above 5 mcg/mL. Discontinue metformin and escalate urgently if suspected.

💊 Biguanide · Oral antidiabetic

Metformin: Nursing Drug Guide, Lactic Acidosis & Hold Rules

First-line oral therapy for type 2 diabetes—but the bedside danger is rare, life-threatening metformin-associated lactic acidosis when renal function drops, contrast imaging, dehydration, hypoxia, or hepatic impairment allow lactate to accumulate. Nurses must verify eGFR before every start or restart, hold for iodinated contrast per labeling, and never dismiss subtle malaise or abdominal pain as “just GI upset.”

⏱️14 min read

📅Updated May 29, 2026

✓Pharmacist Reviewed

✍️

Written by

Sid A. Abdala Balal

🧪

Reviewed by

Kim Serra

Pharmacist

🚨 Boxed warning — Metformin-associated lactic acidosis

Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms may be subtle: malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory findings can include elevated lactate, anion gap acidosis without ketonuria, and metformin plasma levels generally above 5 mcg/mL. Risk increases with renal impairment, contrast procedures, surgery, hypoxia, alcohol, hepatic impairment, and age over 65. If lactic acidosis is suspected, discontinue metformin immediately, provide supportive care in a hospital setting, and arrange prompt hemodialysis per labeling.

📋 Contents

⚡ Quick facts

💊

Class

Biguanide

➡️

Route

Oral

📐

Usual adult start

500 mg BID or 850 mg daily

⚠️

Main risk

Lactic acidosis

💡 Key takeaway

Metformin is not high-alert for wrong-drug mix-ups, but it carries a boxed warning for lactic acidosis. Before every dose at initiation or restart, confirm eGFR is at least 30 mL/min/1.73 m², hold for contrast and acute illness with dehydration, and escalate subtle systemic symptoms—not only GI complaints. Alone it rarely causes hypoglycemia; risk rises when combined with insulin or insulin secretagogues.

💊

Most common brand names

Metformin hydrochloride is available as immediate-release tablets, extended-release products, and oral solution. Verify formulation on the MAR—extended-release tablets must not be crushed unless pharmacy confirms.

Common brands: Glucophage and Glucophage XR; Fortamet; Glumetza; Riomet (oral solution). Many generic metformin hydrochloride tablets (500 mg, 850 mg, 1000 mg) and combination products with other antidiabetic agents appear on formularies.

🎯

Why we give it — Indications

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. It is not insulin replacement and does not treat type 1 diabetes or diabetic ketoacidosis.

Use	Detail
Type 2 diabetes (adults and pediatrics ≥10 years)	First-line oral agent with diet and exercise; may combine with insulin or other agents per prescriber plan
Not indicated	Type 1 diabetes, DKA, or acute/chronic metabolic acidosis

On a small screen, swipe or scroll sideways to see the full table.

🔬

How it works

Metformin is a biguanide that lowers hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity. Unlike sulfonylureas, it does not stimulate insulin secretion—so hypoglycemia is uncommon when metformin is used alone. Nursing relevance: the drug can accumulate when renal clearance falls, increasing lactate and the risk of metformin-associated lactic acidosis.

📐

Dosing overview

Obtain eGFR before initiation and at least annually (more often in older adults and patients at risk for renal decline). Do not start or continue when eGFR is below 30 mL/min/1.73 m².

Adult start

500 mg BID or 850 mg daily

With meals; titrate by 500 mg weekly or 850 mg every 2 weeks

Adult maximum

2550 mg/day

Divided doses; doses above 2000 mg may be better tolerated three times daily with meals

Pediatric (≥10 years)

500 mg BID start

Increase by 500 mg weekly; maximum 2000 mg/day in divided doses twice daily

Renal thresholds

eGFR-based

Contraindicated <30; initiation not recommended 30–45; reassess if <45 on therapy; discontinue if <30

Iodinated contrast

Discontinue at the time of, or prior to, iodinated contrast when eGFR is 30–60 mL/min/1.73 m²; with history of liver disease, alcoholism, or heart failure; or when intra-arterial iodinated contrast will be used. Re-evaluate eGFR 48 hours after the procedure and restart only if renal function is stable per prescriber and protocol.

Missed dose: Not specified in the reviewed prescribing information. Do not double doses. Follow prescriber and facility protocol.

⏱️

Onset, peak, duration, and half-life

Parameter	Value	Nursing relevance
Absorption	Oral; food decreases and slightly delays absorption	Give with meals to improve GI tolerability per labeling
Plasma half-life	Approximately 6.2 hours (labeling)	Renal elimination predominates—dose accumulation when eGFR falls
Elimination	Renal tubular secretion; ~90% eliminated in urine within 24 hours	Hold when acute kidney injury, contrast nephropathy, or dehydration threatens clearance
Dialysis	Dialyzable; clearance up to 170 mL/min under good hemodynamic conditions	Hemodialysis recommended for suspected lactic acidosis and may remove accumulated drug in overdose

On a small screen, swipe or scroll sideways to see the full table.

🛡️

Before you give it — Safety check

Pretreatment checks

Most recent eGFR or creatinine—and trend if contrast, illness, or diuretic therapy is active
Signs of dehydration, hypoperfusion, hypoxia, or acute illness; review intake and output
Scheduled iodinated contrast or surgery—confirm hold orders and restart plan
Concurrent insulin, secretagogues, alcohol use, and carbonic anhydrase inhibitors
Complete medication reconciliation at admission and before contrast

Contraindications

eGFR below 30 mL/min/1.73 m² (severe renal impairment)
Hypersensitivity to metformin
Acute or chronic metabolic acidosis, including DKA with or without coma
Hepatic impairment—avoid use per labeling

Important interactions

Drug / factor	Effect	Nursing action
Insulin glargine / secretagogues (e.g., glipizide)	Increased hypoglycemia risk; lower doses may be needed	Increase glucose monitoring when combination starts or doses change
Carbonic anhydrase inhibitors (e.g., topiramate)	Increased lactic acidosis risk	Notify pharmacy; monitor for acidosis symptoms
Drugs reducing metformin clearance (cimetidine, dolutegravir, ranolazine, vandetanib)	Increased metformin accumulation	Pharmacy review; consider more frequent renal monitoring
Alcohol	Potentiates lactate effects	Teach to avoid excessive alcohol; assess intake on admission
Loop diuretics (e.g., furosemide)	Dehydration and renal hypoperfusion may worsen acidosis risk	Track I&O, weight, and renal function during diuretic bursts

On a small screen, swipe or scroll sideways to see the full table.

➡️

Administration

Route: Oral with meals to reduce GI adverse effects. Swallow extended-release tablets whole unless pharmacy directs otherwise.

Verify eGFR meets institutional criteria before giving a held dose after contrast or acute illness
Pair administration review with blood glucose monitoring when insulin or secretagogues are co-prescribed
Document hold reason, contrast timing, and prescriber/pharmacy communication for delayed doses

⚠️Contrast and NPO periods

Metformin may continue with meals when renal function is stable, but labeling requires discontinuation around iodinated contrast in at-risk patients. Do not restart after imaging until eGFR is reassessed at 48 hours and is stable per protocol—even if the patient is eating again.

📈

Expected therapeutic response

Improved fasting and postprandial glucose over days to weeks
Gradual reduction in HbA1c when diet, activity, and adherence are consistent
Modest weight stability or loss compared with some other antidiabetic classes—monitor for unintended rapid weight loss with acidosis symptoms

🚨

Red flags — Stop and act

Discontinue metformin and escalate urgently if lactic acidosis is suspected:

Malaise, myalgias, respiratory distress, somnolence, or worsening abdominal pain—especially with acute illness or declining renal function
Confusion, hypotension, hypothermia, or resistant bradyarrhythmias
Acute kidney injury, anuria, or eGFR falling below 30 mL/min/1.73 m² while on therapy
Persistent vomiting or dehydration with inability to maintain oral intake during acute illness
Serious hypersensitivity or lactic acidosis after overdose

⚠️

Adverse effects

Adverse effect	Frequency / context	Nursing response
Diarrhea	53% in clinical trials (vs 12% placebo); most common GI effect	Take with meals; slow titration; differentiate from infectious diarrhea during acute illness
Nausea / vomiting	Common (>5% labeling); often dose-related	Assess hydration and renal function; hold if cannot maintain intake per protocol
Vitamin B12 deficiency	Subnormal B12 in ~7% over 29-week trials	Annual hematologic labs; B12 every 2–3 years; supplement or discontinue per prescriber
Hypoglycemia	Rare with metformin alone; increased with insulin/secretagogues	Monitor glucose; anticipate dose reductions when combinations intensify
Lactic acidosis	Rare but serious (boxed warning)	Stop drug; hospitalize; hemodialysis per labeling; contact toxicology per protocol

On a small screen, swipe or scroll sideways to see the full table.

☠️

Overdose, toxicity, and antidote

Overdose has occurred with ingestions greater than 50 grams. Hypoglycemia was reported in approximately 10% of overdose cases but no causal association with metformin alone is established. Lactic acidosis was reported in approximately 32% of metformin overdose cases per labeling.

Management

Supportive care in a hospital setting; discontinue metformin
Prompt hemodialysis for suspected lactic acidosis—metformin is dialyzable
No specific antidote—treatment is supportive care and dialysis
Contact local poison control or medical toxicology services per facility protocol

🔤

Look-alike / sound-alike and error prevention

Metformin vs metoclopramide, methotrexate, or metoprolol—verify generic name and indication (diabetes vs GI, oncology, or cardiac)
Immediate-release vs extended-release—different titration and maximum daily doses; do not substitute at the bedside
Combination tablets—confirm whether product contains a second agent (e.g., sulfonylurea) before administering
“Held for contrast” not communicated—restart only after eGFR check; premature restart after CT is a common safety gap
Home metformin plus inpatient order—reconcile to prevent duplicate therapy

🛏️

Practical bedside notes

Topic	Bedside guidance
Contrast pathway	Place metformin hold on MAR when radiology books iodinated contrast in at-risk patients; set 48-hour eGFR reminder
Acute illness	Hold when vomiting, dehydration, or sepsis threatens renal perfusion until prescriber reviews
GI start-up	Expect diarrhea early—often improves; do not dismiss new systemic symptoms as “only GI”
Surgery	Follow facility perioperative metformin hold/restart rules aligned with labeling risk factors
Commonly missed	Restarting after contrast without eGFR; continuing when creatinine rises after diuretics or AKI
Ask pharmacy when	eGFR 30–45 at initiation, interacting drugs added, or suspected accumulation with subtle acidosis symptoms

On a small screen, swipe or scroll sideways to see the full table.

👥

High-risk populations

Population	Considerations
Renal impairment / chronic kidney disease	Contraindicated if eGFR <30; initiation not recommended 30–45; discontinue if eGFR falls below 30 while on therapy
Age >65 years	Higher lactic acidosis risk; assess renal function more frequently
Contrast, surgery, hypoxia, heart failure	Hold per labeling; restart only when stable
Hepatic impairment	Avoid use—impaired lactate clearance increases acidosis risk
Pregnancy	Labeling notes premenopausal females should be advised of unintended pregnancy potential; poorly controlled diabetes in pregnancy (including gestational diabetes) carries maternal and fetal risk—use only when benefit justifies risk per prescriber
Lactation	Low levels in human milk with low infant exposure in studies; monitor breastfed infant for GI effects per LactMed and prescriber guidance

On a small screen, swipe or scroll sideways to see the full table.

📊

Monitoring and documentation

Monitor

eGFR before initiation and at least annually—more often if renal risk, contrast, or acute illness
Fasting glucose and basic metabolic panel components when acidosis, AKI, or electrolyte shifts are suspected
HbA1c per diabetes care plan
Hematologic parameters annually; vitamin B12 every 2–3 years
Signs of lactic acidosis and volume status (I&O, weight) during acute illness or diuretic therapy

Document

eGFR value supporting administration or hold; contrast date and 48-hour reassessment
Hold reason, prescriber/pharmacy notification, and restart orders
Patient teaching on GI effects, alcohol, contrast instructions, and when to seek urgent care

💬

Patient teaching

Take with meals to reduce stomach upset; swallow extended-release tablets whole unless told otherwise
Report persistent nausea, vomiting, unusual fatigue, muscle pain, trouble breathing, or abdominal discomfort—especially during illness
Avoid excessive alcohol; maintain fluids during acute illness
Before CT or other iodinated contrast, ask when to stop and restart metformin—and complete the scheduled blood work after imaging
Metformin alone rarely causes low blood sugar; risk increases if you also take insulin or pills that stimulate insulin—know hypoglycemia symptoms

✋

The Hold Rule

Do not give and contact the prescriber/pharmacist when:

✋The Hold Rule — When to pause and clarify

eGFR below 30 mL/min/1.73 m² or acute kidney injury with declining renal function
Acute or chronic metabolic acidosis, including DKA
Iodinated contrast in at-risk patients per labeling (eGFR 30–60, liver disease, alcoholism, heart failure, or intra-arterial contrast)—hold until 48-hour eGFR is stable
Acute illness with dehydration, hypoperfusion, hypoxia, or inability to maintain oral intake
Suspected metformin-associated lactic acidosis—discontinue immediately and escalate
Major surgery or procedures per institutional perioperative protocol until renal function and clinical status are stable

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

🩺

Clinical practice integration and workflow

Metformin safety is a renal-and-contrast workflow problem as much as a glycemic one. Embed eGFR checks into admission, contrast scheduling, and discharge planning.

1. Check-before-you-give protocol

Right patient, drug, dose, formulation (IR vs ER), route, and time with meals
eGFR or creatinine within acceptable range for administration or restart
No active contrast hold, NPO dehydration, or suspected acidosis
Review new diuretics, NSAIDs, ACE inhibitors, and interacting drugs with pharmacy

2. High-alert and safety badge

Not a high-alert medication — boxed warning for lactic acidosis applies

Use renal and contrast hold discipline comparable to high-alert workflows even though metformin is not on ISMP high-alert lists for product mix-ups.

3. Clinical workflow: hold and question rules

Contrast booked without metformin hold in eGFR 30–60: contact pharmacy and radiology scheduling
Creatinine rising after diuretic or sepsis: hold metformin and notify prescriber before next dose
Patient reports “flu-like” symptoms with poor intake: evaluate for acidosis, not only viral illness

4. Critical teach-back questions

“When should you stop metformin before a CT scan?” (Patient should describe following prescriber/facility instructions and completing post-imaging blood work before restarting.)
“What symptoms mean you should seek urgent care while on metformin?” (Patient should name breathing difficulty, severe fatigue, vomiting with dehydration, or unusual abdominal pain—not only high glucose.)

5. Care coordination

Pharmacist: eGFR interpretation, contrast hold/restart, drug interactions, and accumulation risk

Prescriber / diabetes team: Dose titration, combination therapy, perioperative plan, and acidosis escalation

Radiology / surgery: Timing of iodinated contrast and coordinated metformin interruption

🧠 Quick mental checklist

What is the most recent eGFR—and is a contrast study within 48 hours?
Is the patient dehydrated, hypoxic, or in metabolic acidosis?
Are insulin or secretagogues on the chart increasing hypoglycemia risk?
Is this immediate-release or extended-release metformin?
Could new fatigue or abdominal pain be lactic acidosis—not only GI upset?

📚

Metformin NCLEX practice questions

Practice NCLEX-style clinical judgment practice for metformin lactic acidosis prevention using a tabbed inpatient case (MAR, labs, I&O, nursing notes), then priority action, cue recognition (SATA), renal and lactate trend interpretation, matrix urgency matching, clinical judgment on contrast holds, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

Select a tab to view MAR, labs, I&O, and nursing note details for this case.

MAR — 72-year-old with type 2 diabetes

Metformin 1000 mg PO BID with meals — held since yesterday for CT abdomen with IV contrast
Insulin glargine 20 units subcutaneous HS
Furosemide 40 mg PO daily — given 0800 today
CT with iodinated contrast completed 36 hours ago; eGFR check due today per protocol

Question 1 — Priority action

After reviewing the case tabs, the nurse notes metformin remains held but the patient has rising creatinine, elevated lactate, and symptoms after iodinated contrast. Which action should the nurse take FIRST?

Administer the held metformin 1000 mg with lunch because the patient is eating again Hold metformin, notify prescriber/pharmacy of post-contrast renal decline and possible lactic acidosis, and escalate monitoring per protocol Give only half the metformin dose because glucose is 142 mg/dL Document symptoms and recheck glucose in 4 hours without notifying the team

Question 2 — Recognize cues

After reviewing the MAR, Labs, I&O, and Nursing notes tabs, which findings increase this patient’s risk for metformin-associated lactic acidosis? Select all that apply

eGFR decreased from 52 to 38 mL/min/1.73 m² after iodinated contrast Elevated lactate with low bicarbonate and nonspecific malaise/abdominal discomfort Negative ketones with glucose 142 mg/dL Recent furosemide therapy with net negative fluid balance and hypotension Age 72 years with recent radiologic study using contrast

Question 3 — Trend interpretation

The team continues supportive care with metformin held. Four hours later:

Trend snapshot
Lactate: 4.8 → 5.6 mmol/L
Bicarbonate: 18 → 16 mEq/L
BP: 98/56 → 88/50 mmHg; HR 104 → 118
Creatinine stable at 2.1 mg/dL; metformin not restarted
Nephrology consulted; hemodialysis discussed

Select all that apply — evaluate outcomes

Worsening lactate and bicarbonate despite metformin hold indicates clinical deterioration Stable creatinine alone means acidosis has resolved Nurse should continue serial lactate, renal, and hemodynamic monitoring and support urgent escalation It is appropriate to restart metformin now because contrast was more than 24 hours ago Hemodialysis may be indicated per labeling when acidosis is suspected—coordinate with prescriber and nephrology

Question 4 — Matrix judgment

For each finding from the case tabs, select the best nursing urgency category (one per row).

Finding	Expected	Concerning	Urgent
Post-contrast day 2; eGFR 48 mL/min/1.73 m²; asymptomatic; metformin held; lactate WNL
eGFR 38 after contrast with creatinine rise; metformin appropriately held; lactate pending
Lactate 5.6 mmol/L, bicarbonate 16, hypotension, abdominal pain—metformin held but symptoms worsening
Family requests metformin restart “because she is eating” while eGFR still 38 and lactate elevated

On a small screen, swipe or scroll sideways to see the full table.

Question 5 — Clinical judgment

A patient with eGFR 55 mL/min/1.73 m² is scheduled for iodinated CT contrast tomorrow. Home metformin 1000 mg twice daily is on the MAR. Which nursing action best reflects labeling and safe practice?

Continue metformin through the procedure because eGFR is above 30 Coordinate metformin hold at or before contrast per protocol, document 48-hour eGFR reassessment before restart, and educate the patient Stop metformin permanently after any contrast study Double the metformin dose after contrast to compensate for held doses

Question 6 — Cloze

Metformin is contraindicated when eGFR is below . If metformin-associated lactic acidosis is suspected, treatment includes discontinuing the drug, supportive hospital care, and prompt per labeling. There is no specific antidote.

Answer key & rationale

Next step Timed NCLEX Next Gen–style scenarios on NurseOnShift

❓

Frequently asked questions

📚

References

🔐

Review and transparency

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.

Metformin: Nursing Drug Guide, Lactic Acidosis & Hold Rules

📋 Contents

⚡ Quick facts

💡 Key takeaway

Most common brand names

Why we give it — Indications

How it works

Dosing overview

Iodinated contrast

Onset, peak, duration, and half-life

Before you give it — Safety check

Pretreatment checks

Contraindications

Important interactions

Administration

Expected therapeutic response

Red flags — Stop and act

Adverse effects

Overdose, toxicity, and antidote

Management

Look-alike / sound-alike and error prevention

Practical bedside notes

High-risk populations

Monitoring and documentation

Monitor

Document

Patient teaching

The Hold Rule

Clinical practice integration and workflow

1. Check-before-you-give protocol

2. High-alert and safety badge

3. Clinical workflow: hold and question rules

4. Critical teach-back questions

5. Care coordination

🧠 Quick mental checklist

Metformin NCLEX practice questions

Answer key & rationale

Frequently asked questions

When should a nurse hold metformin?

What eGFR is required to start or continue metformin?

What are warning signs of metformin-associated lactic acidosis?

Should metformin be held for CT contrast?

Does metformin cause hypoglycemia by itself?

References

Related Topics

Hyperglycemia Symptoms

Insulin Administration

Glucagon

Serum Creatinine

Diabetes Type 1

Anaphylaxis

Review and transparency